Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term treatment study of adagrasib-based therapy in participants from prior BMS adagrasib solid tumor studies
jRCT2061260044Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Open-label trial of adagrasib in Nonhematologic neoplasms (10 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Long-term safety of adagrasib administered as monotherapy or in combination with other cancer therapies. Started Oct 2026; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2061260044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260044.